1-7 of 7
Brian Dougherty
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, Rafael D. White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David Jenkins, Andrew Mortlock, Alessandra Forcina, Veerendra Munugalavadla, Ian Flinn
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3301–3312.
https://doi.org/10.1158/1078-0432.CCR-22-2483
Published: 01 September 2023
View article titled, Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Open the PDF for Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment in another window
Includes: Supplementary data
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View article titled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Robert L. Hollis, Alison M. Meynert, Caroline O. Michie, Tzyvia Rye, Michael Churchman, Amelia Hallas-Potts, Ian Croy, W. Glenn McCluggage, Alistair R.W. Williams, Clare Bartos, Yasushi Iida, Aikou Okamoto, Brian Dougherty, J. Carl Barrett, Ruth March, Athena Matakidou, Patricia Roxburgh, Colin A. Semple, D. Paul Harkin, Richard Kennedy, C. Simon Herrington, Charlie Gourley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-22-0368
Published: 15 August 2022
View article titled, Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Open the PDF for Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification in another window
Includes: Supplementary data
Journal Articles

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R. Grimes, Robert L. Hollis, C. Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson, Mairi Lennie, Trevor McGoldrick, Neil McPhail, Nadeem Siddiqui, Suzanne Dowson, Rosalind Glasspool, Melanie Mackean, Fiona Nussey, Brian McDade, Darren Ennis, Lynn McMahon, Athena Matakidou, Brian Dougherty, Ruth March, J. Carl Barrett, Iain A. McNeish, for the Scottish Genomes Partnership, Andrew V. Biankin, Patricia Roxburgh, Charlie Gourley, Colin A. Semple
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (11): 3201–3214.
https://doi.org/10.1158/1078-0432.CCR-20-4068
Published: 01 June 2021
View article titled, Structural Variants at the <em>BRCA1/2</em> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Open the PDF for Structural Variants at the <em>BRCA1/2</em> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract A63: Examination of ctDNA false positive variants reported from commercial vendors by ultrasensitive orthogonal testing

Daniel Stetson, Ambar Ahmed, Barrett Nuttall, Tristan Lubinski, J. Carl Barrett, Brian Dougherty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A63.
https://doi.org/10.1158/1557-3265.LiqBiop20-A63
Published: 01 June 2020
View article titled, Abstract A63: Examination of ctDNA false positive variants reported from commercial vendors by ultrasensitive orthogonal testing
Journal Articles

Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC

Cath Eberlein, Katie Al-Kadhimi, Sarah Ross, Henry Brown, Paul Fisher, Daniel Stetson, Zhongwu Lai, Kenneth Thress, Brian Dougherty, William Pao, Darren Cross
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): PR05.
https://doi.org/10.1158/1557-3265.PMS14-PR05
Published: 13 February 2015
View article titled, Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC
Journal Articles

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

Justin Guinney, Charles Ferté, Jonathan Dry, Robert McEwen, Gilles Manceau, KJ Kao, Kai-Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean-Charles Soria, Stephen Friend, Jonathan Derry, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 265–272.
https://doi.org/10.1158/1078-0432.CCR-13-1943
Published: 05 January 2014
View article titled, Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Open the PDF for Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients in another window
Includes: Supplementary data